Apixaban 2.5 mg film-coated tablets Ireland - English - HPRA (Health Products Regulatory Authority)

apixaban 2.5 mg film-coated tablets

renata pharmaceuticals (ireland) limited - apixaban - film-coated tablet - apixaban

Apixaban 5 mg film-coated tablets Ireland - English - HPRA (Health Products Regulatory Authority)

apixaban 5 mg film-coated tablets

renata pharmaceuticals (ireland) limited - apixaban - film-coated tablet - apixaban

M-APIXABAN TABLET Canada - English - Health Canada

m-apixaban tablet

mantra pharma inc - apixaban - tablet - 2.5mg - apixaban 2.5mg

M-APIXABAN TABLET Canada - English - Health Canada

m-apixaban tablet

mantra pharma inc - apixaban - tablet - 5mg - apixaban 5mg

TARO-APIXABAN TABLET Canada - English - Health Canada

taro-apixaban tablet

sun pharma canada inc - apixaban - tablet - 2.5mg - apixaban 2.5mg

TARO-APIXABAN TABLET Canada - English - Health Canada

taro-apixaban tablet

sun pharma canada inc - apixaban - tablet - 5mg - apixaban 5mg

TEVA-APIXABAN TABLET Canada - English - Health Canada

teva-apixaban tablet

teva canada limited - apixaban - tablet - 2.5mg - apixaban 2.5mg

TEVA-APIXABAN TABLET Canada - English - Health Canada

teva-apixaban tablet

teva canada limited - apixaban - tablet - 5mg - apixaban 5mg

Apixaban Accord European Union - English - EMA (European Medicines Agency)

apixaban accord

accord healthcare s.l.u. - apixaban - venous thromboembolism; stroke; arthroplasty - antithrombotic agents - prevention of venous thromboembolic events (vte) in adult patients who have undergone elective hip or knee replacement surgery.prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (nvaf), with one or more risk factors, such as prior stroke or transient ischaemic attack (tia); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (nyha class ≥ ii).treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults (see section 4.4 for haemodynamically unstable pe patients).prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (nvaf), with one or more risk factors, such as prior stroke or transient ischaemic attack (tia); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (nyha class ≥ ii).treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults (see section 4.4 for haemodynamically unstable pe patients).